Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2023 Net Income-$3.17M-$3.17MN/M vs Q3 2023 EPS Diluted-$0.85-$0.85N/M vs Q3 2023 Operating Income-$3,626,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,654,000N/M Free Cash Flowderived-$3,654,000N/M ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end